Register for email alerts and news feeds:
This journal | BMJ Group
rss
Ann Rheum Dis. Published Online First: 26 October 2009. doi:10.1136/ard.2009.108639
Copyright © 2009 BMJ Publishing Group Ltd & European League Against Rheumatism.

Extended Report

Early treatment with and time on first Disease Modifying Anti-Rheumatic Drug predicts long-term function in patients with inflammatory polyarthritis

Tracey M Farragher1, Mark Lunt1, Bo Fu1, Diane Bunn2, Deborah Symmons1,*

1 University of Manchester, United Kingdom;
2 Norfolk and Norwich University Hospital, United Kingdom

Correspondence to: Deborah Symmons, ARC Epidemiology Unit, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, United Kingdom; deborah.symmons{at}manchester.ac.uk

Accepted 3 October 2009

ABSTRACT

Objectives: To investigate the influence of early disease modifying anti-rheumatic drug (DMARD) treatment on long-term functional outcome in patients with recent onset inflammatory polyarthritis (IP), and the impact of the duration of first and subsequent DMARD treatment.

Methods: 642 subjects from a primary-care registry of patients with new onset IP, recruited 1990-1994, were followed for 10 years. Mean change in HAQ scores between baseline and 10 years were compared by time to and time on first DMARD treatment and total time on treatment, using linear regression. Adjustment for time dependent confounders and censoring was performed using marginal structural weights.

Results: When adjusted for baseline and subsequent disease severity, those treated early (<6 months from symptom onset) experienced a non-significant improvement in function compared to those never treated (adjusted mean difference in change (adj_MDIC) in HAQ -0.24; 95% CI -0.58, 0.09); and a significant benefit for each additional month of treatment within 6 months of the onset of symptoms (adj_MDIC -0.10 95% CI; -0.19, -0.02). Patients who discontinued their first DMARD within 6 months experienced a significant deterioration in long-term function (adj_MDIC in HAQ 0.28 95% CI; 0.04, 0.52), while those who continued their first therapy for greater than 3 years experienced an improvement (adj_MDIC in HAQ -0.37; 95% CI -0.77, 0.04).

Conclusions: We have demonstrated the importance of time to and response to first DMARD treatment and total duration of DMARD treatment in modifying the 10 year function in patients with IP.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs